Hypertension Workgroup

The consortium identified hypertension as the focus area for its common disease workgroup. Floridians consistently identify high blood pressure as a top health concern, and clinicians routinely identify that condition as a critical issue for their patients. The workgroup is led by Rhonda Cooper-DeHoff, Pharm.D., M.S., FAHA, FACC, of the University of Florida. Cooper-DeHoff is also a prominent member on the PCORI Cardiovascular Health Collaborative Research Group.

The National Patient-Centered Clinical Research Network (PCORnet) has selected the consortium as a participant in two large-scale national clinical trials related to hypertension, ADAPTABLE and INVESTED.  The Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) trial seeks to determine the ideal dosage of aspirin for patients to prevent heart attacks. The second trial, entitled Influenza Vaccine to Effectively Stop CardioThoracic Events and Decompensated Heart Failure (INVESTED), investigates the role of high-dose influenza vaccine in reducing cardiovascular events, since several analyses have shown that the vaccine provides cardiovascular benefits, particularly at high doses. In addition, the workgroup is facilitating the completion of three investigator-initiated studies.



  • List out presentations given by group members
  • Or presentations given to group members
  • One by one
  • Include date, ant title name. Link to slides maybe

Contact Information

For more information about the OneFlorida Hypertension workgroup, please contact Damian Alderman at celxius@ufl.edu.


Rhonda Cooper-DeHoff